Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 89
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02299518 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | ||
| NCT04562870 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis | ||
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | ||
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | ||
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | ||
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | ||
| NCT03555422 | Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO] | ||
| NCT02137356 | Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer | ||
| NCT02120222 | Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery | ||
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | ||
| NCT03042819 | Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas | ||
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer) | ||
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | ||
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | ||
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | ||
| NCT02093403 | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT02138786 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | ||
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | ||
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | ||
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | ||
| NCT02091245 | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | ||
| NCT02471911 | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | ||
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | ||
| NCT02384850 | Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer | ||
| NCT04349098 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | ||
| NCT02606461 | Selinexor in Advanced Liposarcoma | ||
| NCT04854434 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | ||
| NCT03466827 | Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma | ||
| NCT02078349 | Phase I Study of KPT330 in Asian Patients | ||
| NCT04562389 | Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis | ||
| NCT02431351 | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | ||
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | ||
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | ||
| NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | ||
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | ||
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | ||
| NCT04607772 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | ||
| NCT03095612 | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | ||
| NCT02436707 | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | ||
| NCT02228525 | Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes | ||
| NCT02250885 | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | ||
| NCT04661137 | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | ||
| NCT04925193 | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | ||
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | ||
| NCT02402764 | Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) | ||
| NCT05530421 | Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma | ||
| NCT02336815 | Selinexor Treatment of Refractory Myeloma | ||
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | ||
| NCT02367690 | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients |
